Where is apogee Therapeutics (apge) based?

Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. A high-level overview of Apogee Therapeutics, Inc. (APGE) stock.

Is apogee Enterprises a good stock to buy?

Apogee Enterprises has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings. According to analysts' consensus price target of $48.00, Apogee Enterprises has a forecasted downside of 16.3% from its current price of $57.34.

How many investors does apogee therapeutics have?

Apogee Therapeutics has 9 investors including RTW Investments and Fidelity Management and Research Company. How much funding has Apogee Therapeutics raised to date? Apogee Therapeutics has raised . When was the last funding round for Apogee Therapeutics? Apogee Therapeutics closed its last funding round on Dec 7, 2022 from a Series B round.